Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

Promising results from Merck's mRNA melanoma vaccine trial were presented at a European cancer conference this weekend. The data indicates that the vaccine, when used alongside an immunotherapy drug, reduces the recurrence of melanoma and the risk of death from skin cancer.